Pituitary adenoma & nuclear medicine: Recent outcomes and ongoing developments

Area of Science:

• Endocrinology and Nuclear Medicine
• Oncology and Radiology

Background:

• Magnetic resonance imaging (MRI) is the primary tool for pituitary adenoma (PA) diagnosis but has limitations and can be inconclusive.
• There is a need for advanced imaging techniques to improve PA diagnosis, management, and follow-up.
• Nuclear medicine offers functional and molecular insights beyond anatomical information provided by MRI.

Purpose of the Study:

• To review the performance and clinical utility of various nuclear medicine radiotracers for pituitary adenoma.
• To discuss the role of nuclear medicine in confirming PA diagnosis and guiding patient management.
• To explore the therapeutic applications of nuclear medicine, including Peptide Receptor Radionuclide Therapy (PRRT).

Main Methods:

• Utilizes nuclear medicine imaging modalities such as single photon emission computed tomography (SPECT) and positron emission tomography (PET), often combined with CT.
• Employs radiopharmaceuticals that target specific cellular elements and biological pathways within pituitary adenomas.
• Reviews existing literature on radiotracer performance and clinical applications in PA.

Main Results:

• Nuclear medicine techniques provide complementary information to MRI, aiding in the confirmation of PA diagnosis.
• Specific radiotracers show promise in visualizing and characterizing pituitary adenomas.
• Peptide Receptor Radionuclide Therapy (PRRT) is emerging as a therapeutic option for aggressive PA and pituitary carcinoma.

Conclusions:

• Nuclear medicine imaging is a valuable tool for pituitary adenoma diagnosis, management, and follow-up, especially when MRI is inconclusive.
• Radiopharmaceuticals offer insights into PA biology and have therapeutic potential.
• Further research into radiotracer development and PRRT is crucial for optimizing PA care.